• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

MicroRNA 155 and viral-induced neuroinflammation

Jackb23

Senior Member
Messages
293
Location
Columbus, Ohio
The study isn't particularly new but it is not old either. I know that miRNA-155 has been touched on within this website before and I believe this study to also be pertinent to ME/CFS.



MicroRNA 155 and viral-induced neuroinflammation
Laura L. Dickey, Timothy M. Hanley, Thomas B. Huffaker, Andrew G. Ramstead, Ryan M. O'Connell, Thomas E. Lane


"
Alejandro et al. (Lopez-Ramirez et al., 2014) discovered that miR-155 is upregulated in neurovascular units in active MS lesions compared to normal-appearing white matter in MS patients. In addi- tion, the group used the EAE model to show that miR-155 expression is dramatically increased in mice with hind-limb paralysis during the recovery phase, and that miR-155 regulates blood-brain-barrier (BBB) function. The latter finding is consistent with a study byLopez-Ramirezet al. (2014) showing that miR-155 negatively regulates blood-brain-barrier permeability by targeting the cell-cell complex mol- ecules annexin-2 and claudin1, as well as the adhesion components DOCK-1 and syntenin-1."


"Not surprisingly, multiple reports identify miR-155 as important in mediating host responses to microbial diseases (Zeng et al., 2015), in- cluding viral infections with members of the Herpesviridae,Coronaviridae, Arenaviridae, Flaviviridae, and Retroviridae families (discussed further below) (Yao and Nair, 2014; Kaluzna, 2014; Gottwein, 2013; Bhela et al., 2015; Bhela et al., 2014; Dickey et al., 2016; Dudda et al., 2013; Lind et al., 2013; Lu et al., 2011; Martinez-Nunez et al., 2009; Napuri et al., 2013; Zawislak et al., 2013). Recently, miR-155 has been shown to tailor immune responses in models of viral-induced neurologic disease, and numerous mechanisms by which miR-155 controls immune responses following viral infection have been identified. For example, multiple studies have demonstrated that T cell responses are impaired in the absence of miR-155 during in- fection with certain neurotropic viruses (Lu et al., 2015; Bhela et al., 2015; Bhela et al., 2014; Dickey et al., 2016; Dudda et al., 2013; Lind et al., 2013; Zawislak et al., 2013)."



Mechanisms of miR-155-mediated regulation of neuroinflammation:


Herpes simplex virus:

Modulates disease severity and viral load in CNS Regulates accumulation of CD8+ T cells
Affects number of CD8+ T cells that produce TNF-αand/or IFN-γ
Necessary for optimal expression of homing molecules VLA-4 and CD44
Important for Th1 and Th17 cell accumulation in lymph nodes and spleens
Promotes CD4+ T cell proliferation
Regulates expression of IL-1β, IL-6, IFN-γ, and IL-16 Regulates levels of SHIP1 and IFN-γRα in activated CD4+ T cells



Cytomegalovirus:

Critical for expansion of effector NK cells
Regulates survival of NK cells
Necessary for optimal memory NK cell generation Targets Noxa and SOCS1



Lymphocytic choriomeningitis virus:

Necessary for optimal CD4+ and CD8+ T cell responses Necessary for optimal CD8+ T cell proliferation Necessary for optimal CD8+ T cell survival by interfering with PI3/Akt pathway
Regulates cytokine signaling by targeting SOCS1
Targets SOCS1 to regulate expansion of virus-specific NK cells
Targets SOCS1 to regulate maintenance of virus-specific CD8+ T cells during chronic infection



Japanese encephalitis virus:

Mediates disease severity
Regulates expression of IFN-β, TNF-α, IL-10, MCP-1, IL-6, IRF-3/7, IRF-8, CFH, and TBK-1
Negatively regulates SHIP1 expression
Contributes to JEV-induced microglial activation and neuronal death"





http://labs.path.utah.edu/oconnell/publications/28139244.pdf